News

Article

HPC Binder Designed for Small Tablets

Ashland introduces Klucel EXF Ultra HPC, a low friability, high strength binder.

Ashland has introduced Klucel EXF Ultra HPC, a tablet binder that was developed to enable drug manufacturers to use smaller-size tablets for patients that have challenges swallowing. The announcement was made in an April 30, 2019 press statement.

The hydroxypropyl cellulose (HPC) excipient has exceptional binder efficiency, compressibility, and plasticity with enhanced tablet strength and low friability at usage levels as low as 1–2%, the company reports. The HPC also features an ultra-fine particle size and is designed to enhance hardness and improve friability, which may reduce defect rates.

Ashland reports that the company introduced HPC more than 65 years ago; the Klucel brand has been used for direct compression and dry granulation. The latest version of the HPC was designed to improve manufacturing costs and patient-centric drug delivery by improving tablet binding effectiveness.

Source: Ashland

 

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Related Content